Apellis Pharmaceuticals Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
February 22, 2023 07:22 ET
|
Apellis Pharmaceuticals, Inc.
WALTHAM, Mass., Feb. 22, 2023 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc., (Nasdaq:APLS), a global biopharmaceutical company and leader in complement, today announced that it has commenced an...
Apellis Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results
February 21, 2023 16:13 ET
|
Apellis Pharmaceuticals, Inc.
SYFOVRE™ (pegcetacoplan injection) approved in the U.S. as the first and only treatment for geographic atrophy (GA) secondary to age-related macular degeneration (AMD)EU marketing authorization...
FDA Approves SYFOVRE™ (pegcetacoplan injection) as the First and Only Treatment for Geographic Atrophy (GA), a Leading Cause of Blindness
February 17, 2023 16:06 ET
|
Apellis Pharmaceuticals, Inc.
SYFOVRE slowed GA progression with increasing effects over time Approved for all patients with GA, with dosing flexibility every 25 to 60 days Well-demonstrated safety profile following ~12,000...
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
February 13, 2023 16:05 ET
|
Apellis Pharmaceuticals, Inc.
WALTHAM Mass., Feb. 13, 2023 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in complement, today announced that the company approved...
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
January 06, 2023 16:05 ET
|
Apellis Pharmaceuticals, Inc.
WALTHAM, Mass., Jan. 06, 2023 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in complement, today announced that the company approved...
Apellis Appoints Leading Retina Specialist Dr. Caroline Baumal as Chief Medical Officer
January 05, 2023 07:00 ET
|
Apellis Pharmaceuticals, Inc.
WALTHAM, Mass., Jan. 05, 2023 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in complement, today announced that leading retina...
Apellis Pharmaceuticals to Present at the 41st Annual J.P. Morgan Healthcare Conference
January 03, 2023 07:00 ET
|
Apellis Pharmaceuticals, Inc.
WALTHAM, Mass., Jan. 03, 2023 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in complement, today announced that the company will...
Apellis Submits Marketing Authorization Application to the European Medicines Agency for Pegcetacoplan for Geographic Atrophy
December 16, 2022 07:00 ET
|
Apellis Pharmaceuticals, Inc.
WALTHAM, Mass., Dec. 16, 2022 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in complement, today announced that the company has...
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
December 07, 2022 16:05 ET
|
Apellis Pharmaceuticals, Inc.
WALTHAM, Mass., Dec. 07, 2022 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in complement, today announced that the company approved...
Apellis Pharmaceuticals to Present at Upcoming Investor Conferences
November 22, 2022 16:05 ET
|
Apellis Pharmaceuticals, Inc.
WALTHAM, Mass., Nov. 22, 2022 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in complement, today announced that the company will...